Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2013-06-11 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2013-06-11 English
3
Director's Dealing
2013-06-11 English
3
Director's Dealing
2013-06-11 English
Regulatory Filings 2013
Regulatory Filings
2013-05-21 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC by OvaScience, Inc. It is a registration statement under the Securities Act of 1933, related to the offering and resale of common stock by selling stockholders. The document includes a prospectus with detailed information about the company, its business, product candidates, risk factors, executive compensation, and other disclosures typical of a registration statement. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and offering, not a report or announcement of financial results or corporate governance changes. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-05-15 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed pursuant to the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2013. It contains detailed unaudited financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. It also includes management's discussion and analysis of financial condition and results of operations. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2013-05-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.